Obituaries
PGe
PG Store
Archives
Classifieds
Classified
Events
Jobs
Real Estate
Legal Notices
Pets
MENU
SUBSCRIBE
LOGIN
REGISTER
LOG OUT
MY PROFILE
Home
News
Local
Sports
Opinion
A&E
Life
Business
Contact Us
NEWSLETTERS
MENU
ACCOUNT
Subscribe
Login
Register
Log out
My Profile
Subscriber Services
Search
SECTIONS
HOME
Homepage
This Just In
Chats
Weather
Traffic
Event Guide
PG Store
PGe
Video
Photos
The Digs
RSS Feeds
NEWS
News Home
COVID-19
World
Nation
State
Obituaries
News Obituaries
Politics
Education
Portfolio
Science
Health & Wellness
Environment
Aging Edge
Transportation
Faith & Religion
Crimes & Courts
Social Services
LOCAL
Local Home
Region
City
North
East
West
South
Washington
Westmoreland
The Neighborhood
Obituaries
Classifieds
Legal Notices
Real Estate
SPORTS
Sports Home
Steelers
Penguins
Pirates
Sports Columns
Gene Collier
Ron Cook
Joe Starkey
Paul Zeise
High School Sports
College Sports
Pitt
Penn State
WVU
NCAA
NFL
MLB
NBA
NHL
North Shore Drive Podcast
OPINION
Opinion Home
Editorials
Letters
Op-Ed Columns
PG Columnists
Insight
A&E
A&E Home
Celebrities
Movies
TV & Radio
Music
Concert Listings
Theatre & Dance
Art & Architecture
Books
Events
LIFE
Life Home
Food
Buying Here
Homes & Gardens
Style & Fashion
Travel
Restaurants
Seen
goodness
Random Acts of Kindness
Pets
Beer Me
Outdoors
Holidays
BUSINESS
Business Home
Your Money
Wheels
Workzone
Business Health
Tech News
Building PGH
Powersource
Business / Law
Top Workplaces
Business of Pittsburgh
Consumer Alerts
OTHER
PGe
NEWSLETTERS
PG STORE
ARCHIVES
CLASSIFIEDS
OBITUARIES
JOBS
LEGAL NOTICES
REAL ESTATE
CLASSIFIEDS
EVENTS
PETS
CONTACT US / FAQ
CONTACT US
ADVERTISING
CAREER OPPORTUNITIES
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Immunic, Inc. - Common Stock
(NQ:
IMUX
)
1.020
+0.072 (+7.63%)
Streaming Delayed Price
Updated: 4:00 PM EST, Feb 27, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Immunic, Inc. - Common Stock
Immunic to Present at the November 21st Virtual Investor Summit Microcap Event
November 11, 2024
Via
ACCESSWIRE
Immunic CMO discusses role of clinical trials in biotech development for Clinical Trials Day
May 20, 2024
Immunic Inc (NASDAQ:IMUX) chief medical officer Dr Andreas Muehler discusses the importance of clinical trials in the biotech industry to mark Clinical Trials Day on May 20.
Via
TheNewswire.com
Immunic chief medical officer discusses promising treatments to mark World IBD Day
May 17, 2024
Immunic Inc (NASDAQ:IMUX) chief medical officer Dr Andreas Muehler discusses Inflammatory Bowel Disease (IBD) with Proactive's Stephen Gunnion to mark World IBD Day on May 19.
Via
TheNewswire.com
Immunic highlights IMU-856 gastrointestinal candidate to mark International Celiac Day
May 16, 2024
Immunic Inc (NASDAQ:IMUX) chief scientific officer Hella Kohlhof joined Proactive's Stephen Gunnion on International Celiac Day, in the middle of Celiac Disease Awareness Month, to discuss the disease...
Via
TheNewswire.com
Immunic CEO Dr Daniel Vitt discusses key Q1 advances and upcoming milestones
May 09, 2024
Immunic Inc (NASDAQ:IMUX) CEO Dr Daniel Vitt takes Proactive's Stephen Gunnion through the company's first-quarter achievements and upcoming milestones for its clinical pipeline of orally administered,...
Via
TheNewswire.com
Topics
Intellectual Property
Immunic Inc set to bring relief with encouraging results
May 16, 2023
Dr Daniel Vitt, CEO of Immunic Inc (NASDAQ:IMUX), discusses the company's encouraging first-quarter performance with Proactive.
Via
TheNewswire.com
Immunic Phase 2 EMPhASIS trial data highlighted in peer-reviewed neurology journal
May 01, 2024
Immunic Inc (NASDAQ:IMUX) CEO Dr Daniel Vitt joined Proactive's Stephen Gunnion with news of the publication of extended data from the Phase 2 EMPhASIS trial of vidofludimus calcium in...
Via
TheNewswire.com
Immunic CMO discusses complexities of multiple sclerosis to mark MS Awareness Month
March 21, 2024
Immunic Inc (NASDAQ:IMUX) Chief Medical Officer Dr Andreas Muehler discusses the complexities of multiple sclerosis (MS) during an interview with Proactive's Stephen Gunnion to mark MS Awareness Month,...
Via
TheNewswire.com
Immunic CSO hails "great" progress with MS program
October 24, 2023
Immunic Inc (NASDAQ:IMUX) Chief Scientific Officer Hella Kohlhof speaks to Thomas Warner at the Proactive London after returning from MSMilan2023, the 9th Joint ECTRIMS-ACTRIMS meeting. She shares some...
Via
TheNewswire.com
Immunic "super excited" about latest PMS trial data
October 11, 2023
Immunic Inc (NASDAQ:IMUX) President and CEO Dr Daniel Vitt speaks to Thomas Warner from Proactive after the biotechnology company announced encouraging interim data from its phase II CALLIPER trial...
Via
TheNewswire.com
Immunic CEO hails "great day" after completing IMU-838 phase 2 trial enrolment
August 21, 2023
Immunic Inc (NASDAQ:IMUX) President and CEO Dr Daniel Vitt speaks to Thomas Warner from Proactive after the biotechnology company announced the completion of the enrolment of its phase 2 CALLIPER trial...
Via
TheNewswire.com
Immunic CEO says Q2 results "couldn't be better"
August 07, 2023
Immunic Inc (NASDAQ:IMUX) president and CEO Dr Daniel Vitt speaks to Thomas Warner from Proactive following the release of the Munich-based biotechnology company's second-quarter financial results and...
Via
TheNewswire.com
Immunic Inc eyeing "big step" for multiple sclerosis patients
July 25, 2023
Immunic Inc (NASDAQ:IMUX) president and CEO Dr Daniel Vitt joined Thomas Warner from Proactive ahead of World Brain Day to provide an update on the biotechnology company's novel multiple sclerosis (MS)...
Via
TheNewswire.com
Immunic IMU-856 trial data "clearly goes beyond" initial expectations
May 04, 2023
Immunic Inc (NASDAQ:IMUX) CEO Dr. Daniel Vitt speaks to Thomas Warner from Proactive after releasing new clinical trial data for the biotechnology company's IMU-856 molecule, which is aimed at...
Via
TheNewswire.com
Immunic gets a "positive surprise" from lead asset trial
April 13, 2023
Immunic Inc (NASDAQ:IMUX) CEO Dr. Daniel Vitt speaks to Proactive following the release of data from the maintenance phase of its phase 2b CALDOSE-1 trial of lead asset vidofludimus calcium (IMU-838)...
Via
TheNewswire.com
Immunic Inc. (NASDAQ: IMUX) Featured in Virtual Coverage of the 34th Annual Roth Conference
March 11, 2022
Via
Investor Brand Network
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
TOP
Email a Story
Your e-mail:
Friends e-mail:
Submit
